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Summary.-The value ofthe leucocyte adherence inhibition (LAI) test in thediagnosis
of hepatocellular carcinoma (HCC) was investigated in 36 patients with this tumour.
The sensitivity and specificity of the tube LAI test was assessed in 21 patients with
HCC, 15 apparently healthy individuals, 9 patients with various forms of benign liver
disease and 5 patients with non-hepatic neoplasms. In only 42% of the HCC patients
tested was leucocyte adherence to glass reduced to a greater extent than in the healthy
controls and in the patients with non-hepatic neoplasms, and the differences were
not statistically significant. Moreover, positive results were obtained in 6/9 patients
with benign hepatic disease. A further 15 patients were tested against extracts of
HCC tissue using the haemacytometer LAI method. Of these, 53o% gave positive
results. In all, only 17/36 patients (47°,) gave positive LAI responses. The test is thus
of limited value in the diagnosis of HCC. The high false-negative result rate may be
due either to abrogation of the immune response in HCC patients with large tumour
burdens or to antigenic heterogeneity in HCC.
MOST MALIGNANT TUMIOURS in man and
experimental animals possess characteris-
tic antigens which permit differential
imm-unoreactivity to be demonstrated
(Hellstrom et al., 1971). A number of
in vitro methods have been used to detect
such reactivity, including cytotoxicity
testing (Jagarlamoody et al., 1971), leuco-
cyte migration inhibition (Bull et al.,
1973), and lymphocyte transformation
(Vainky et al., 1971). More recently the
leucocyte adherence inhibition (LAI) test
has been developed as a simple and rapid
technique for detecting cell-mediated im-
mune response to soluble tumour-associa-
ted antigens (Halliday & Miller, 1972;
Halliday et al., 1974; Grosser & Thomson,
1975). This test has been used in assessing
reactivity to a wide variety of tumours
(Tataryn et al., 1978; Maluish & Halliday,
1974) including hepatocellular carcinoma
(HCC) (Halliday et al., 1974). In the latter
study, positive LAI tests were found in a
few patients with HCC. However, this
observation has not been confirmed, and
the purpose of the present study was to
evaluate the diagnostic usefulness of the
LAI test in a larger number ofpatients.
SUBJECTS STUDIED AND METHODS
Subjects. Twenty-one patients with histo-
logically proven HCC were investigated using
a modification of the tube LAI test. An addi-
tional 16 patients were studied with the
haemacytometer LAI method. The age of the
patients ranged from 22 to 63 years, with a
mean of 45-5 years. Each patient was studied
before treatment wNas begun. All but one of
the patients in whom follow-up information
was obtained had died within 3 months of
diagnosis. The control group consisted of 15
apparently healthy age-matched subjects, 9
patients with benign hepatic disease (6 with
acute viral hepatitis, of whom 4 were hepat-
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itis-B surface-antigen (HBsAg) positive, 1
with chronic active hepatitis (HBsAg-). 1
'ith haemnochromatosis ari(I 1 w-ith a liver
abscess of unknow7n aetiology) and 5 patients
with neoplasms arising in organs other than
the liver (carcinoma of the pancreas, breast,
lung and larynx, and Hodgkin's lymphiorna).
Tumiiour extract. HCC tissue, obtained
mainly from primary foci but also fromn
pulmnonarv metastases, was prepared using
the method of Halliday (1976). Five grams of
frozen HCC tissue -were finely chopped with
sterile scissors and passed through a steel
mesh. This mnaterial was then homogenized
in 4 vols of cold phosphate-buffered saline,
after -which the homogenate -was centrifuged
at 1000 , for 30 rnin at, 4°C. The supernatanit
wxas furthler centrifuged at 20,000 g for 30
min at 4°C. The clear supernatant, freed of
fat particles, was frozen at -20°C overnight.
then tha-wed and centrifuged at, 1000 , for 10
min. These extracts -were stored in 0l15mnl
amounts at -70°C and -were diluted w*ith
inedium on the dav of the tests. All extracts
were used within 2 months of their prepara-
tion. The protein concentration ofthe extracts
wN-as estiiimated bv the biuret method.
Tuibe LAI test.-A 30rnl sample ofheparini-
ized (Panheparin Abbott) venous blood was
layered on to 15 ml of Ficoll-Hypaque in
56ml conical disposable plastic tubes (Falcon).
The tubes -were centrifuged for 40 muin at
room temperature -with an interface force of
400 y. The mnononuclear cells (MN) at the
inter-face -were aspirated. diluted 1: 5 with
rninimal essential medium (MEM- Burroughs
Wellcome), and centrifuged at 400 g for 10
min. The cells -were then -washed x 3, after
w1hich they were resuspended to a concentra-
tion of 4 x 1(7 cells/rnl medium (Rutherford
et al., 1977). Mixtures were mnade of equal
volunmes (041 ml) ofMN suspension with either
diluted tuinour extract or MEM alone.
Medium was then added to bring the final
volurnes to 0(4 mnl, and the tubes were incu-
bated at 37°C for 30 rnin with periodic
shaking. After incubation. leucocyte counts
wTere mnade on each samnple in a Coulter Model
D2 particle counter (Coulter Electronics.
Hertfordshire) as for routine counting of
leucocytes. The remaining cell inixtures were
placed in 10ml glass 'Vacutainer" test tubes
(Becton-Dickenson, New Jersey. U.S.A.) and
these stoppered tubes w-ere then incubated
horizontally at 37°C in a humidified atmos-
phe,re of 50/a CO2 in air for 2 h. After incuba-
tion the tubes were gently placed in an up-
right position and the non-adherent leuco-
cvtes at the bottomn of the tube wtere re-
counted in the Coulter counter. The percent-
age adherence w-as estimated as follows:
0/ adherence=
1 00 post-incubation count initial count
All tests were performed in duplicate and the
results for tubes wtith tumour antigen (A) and
for control tubes containing medium alone
(C) wtere expressed as a % LAI, calculated as
follows:
°h1AI1 CA X1()( CA
V'alues of %0 LAI for the series of patients
-with HCC and for normals were examined
statistically using Wilcoxon's rank-sum test.
Hame#acytonteter LAI test. The technique
of Halliday (1976) w-as used. Leucocytes were
separated by sedimentation from h-eparinized
venous I)lood, the final leucocyte suspensions
containing 2 x 107 cells/ml. Normnal homo-
logous human serum separated from clotted
blood -was stored at -20°C and diluted
with medium before use, giving a 10% coIn-
centration. Duplicate reaction mixtures con-
taining equal volumnes (0.05 ml) of leucocyte
suspension writh either diluted tumour antigen
or mnediumn, and 10% normal human serum
were mixed, -with the addition ofmnediumn to a
final volume of 0-20 ml. Codedl mixtures -were
incubated for 30 min at 37°C and then intro-
duced into Inproved Neubauer haema-
cvtometer chambers. Adherenice of leuco-
cytes to glass -was determined after 1 h of
in-cubation. Cells -were counted withm a Leitz
phase-contrast microscope and the? meani per-
centage leucocyte adlherence a-as calculated
for the antigen mixtures and controls.
Student's t test was used to assess the signifi-
cance of the difference between mneain values.
Th-e LAI test, was considem-ed to be positive if
P<0.05.
RESULTS
Tutbe LAI test
In the healthy conitrols the percentage
leucocyte adherence was not significantly
altered by the addition of 11CC antigen,
the calculated %0 LAI varyinig from -12
to + 11 -9 with a median valtie of + 3-8
(Fig. 1). Addition of HC( antigen pro-
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DISEASES
VICe. Tube leulcocyte adiherence inhibition
in 3 groups of patients ani(l in henaltht
controls.
duced an increase in LAI above the
highest control valtue in 9/21 patients
(42%) with HCC, the median LAI value
being 14-6. However, these results did not
differ significantly from those in the
controls. Clinical and biochemical (letails
of the HCC' patients with elevated LAI
TAIBLE I. LAI reactivity to hepatocellular
cytomCet
Letueoeytes
Normal (S.H.)
(E.C.)
, (T.C.)
HCC (R.D.)
I (R.P.)
, (G.J.)
, (DI.K.)
, (G-H.)
I (V.C.)
I (SNv.)
,, (S.T.)
. (D)a.K.)
\V itlhotit
antigen
71-2
82-6
7:3-6
77-9
89-5
96-3
858-
73.4
59-()
73-7
85
81-)
80X6
AIitigenI
(1)
77-6
9:3-0
8(-8
56-1
79-8
87-0
78-2
65-9
78-5
70 7
70
90-7
(68 5
results were compared with those of the
patients with results within normal limits.
There was no significant difference in age,
sex, presence or absence of ascites or chest
metastases, haemoglobin concentration,
leucocyte count, liver-function tests,
gamma-globulin concentrations, or the
presence of HBsAg. HCC patients with a
negative LAI test were not ac-foetoprotein-
positive (byimmunodiffusion) significantly
more often than those with a positive test.
The 5 patients with malignancies other
than HCC did not show reactivity to the
HCC tumour-antigen extract, in that their
LAI test results fell within the range of
the control group. However, elevated
responses were obtained in 6/9 patients
writh benign hepatic disease (Fig.). Three
of these patients had HBsAg+ acute
hepatitis and were tested 5 weeks after the
onset of the jaundice. One of the 3 showed
a mildly elevated response in the early
stages of his disease, and this increased at
5 wAeeks. A further patient with haemo-
chromatosis had an elevated LAI test,
but to date he has not shown clinical or
other evidence of HCC. Of the other 2
patients with elevated results, one had a
liver abscess and the other had chronic
active HBsAg- hepatitis.
carcinoma (HCC) antiqens asiny the haema-
ter assay
0O Adherence
_ _ _
P*
NSt
NS
NS
< 0-05
NS
NS
NS
XS
NS
NS
< ((-()5
NS
<0-01
AntigeIn
(3)
70-3
NT+
68-3
(;68
81*2
NT
68-5
NT
NT
54-7
S1 ()
NT
NT
P*
NS
NS
NS
N0S
< 0-02
Result
<(0-02 +
NS
* Stuilenit's t test betwecun group)s.
t N'ot significant.
+ Not teste(l.
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Haemacytorneter LAI assay
In preliminary experiments, positive
LAI was not obtained with leucocytes
from normal subjects and antigens derived
from 3 different HCCs or a pooled antigen
from 5 HCCs. Typical examples of results
of 3 normal subjects are shown in Table I.
One antigen extract (Antigen "2") did
not cause LAI with leucocytes from 5
patients with HCC, and further experi-
ments using this antigen were not attemp-
ted. Results of experiments with 2 other
antigens are indicated in Table I. Using
the pooled tumour extract, LAI was not
obtained in normal subjects, but positive
tests were obtained in 3/5 patients with
HCC (Table II).
TABLE II. Haemacytonmeter LAI test on
HCC patients against pooled trnour
antigen
°/0 A(dherenee
HCC Wtithout WNitlh
patients antigeni antigen P*
AI.P. 85-1 69-2 < 0-02
J.R. 83 6 75-1 NSt
J.N. 60-0 39-1 <002
E.M\. 72-7 49-4 < 0-02
L.N. 53-6 57-:3 NS
* Student's t test betxween groups.
t Not significant.
Result
+
DISCUSSION
The immunological basis for the LAI
test is at present imperfectly understood.
Most authors believe that the test is an
indicator of cell-mediated immunity
(Howell, 1979). In the haemacytometer
system T-lymphocyte reactivity and pro-
duction of a lymphokine, leucocyte adher-
ence inhibition factor (LAIF), may be
responsible for reduced leucocyte ad-
herence. Proteases released by tumours
are thought to inactivate LAIF (Halliday,
1979). These proteases may themselves be
inactivated by factors present in serum.
The addition of serum to the test system
used in the detection of LAIF is therefore
necessary. In the tube method, the macro-
phage appears to be the reactive cell, and
reduced macrophage adherence to glass
may be the result of binding of cytophilic
antitumour antibody to macrophage Fe
receptors. In this method serum is not
used, since the addition of serum causes
nonspecific inhibition of leucocyte adher-
ence (Thomson & Crosser, 1979).
In the present study we first used the
tube method. However, in only 42 o of
the patients was there greater LAI than
found in healthy subjects, and the high
false-negative rate in our hands severely
limited the diagnostic usefulness of the
test. Furthermore, this method did not
differentiate between patients with benign
hepatic disease and those with HCC, in
that abnormal responses were obtained in
6/9 patients with various forms of non-
malignant liver disease. This may have
indicated some degree of reactivity by
these patients' leucocytes to normal tissue
antigens released during acute inflam-
matory processes and also present in HCC
extracts. Similar results were obtained by
O'Connor et al. (1978), who reported false-
positive LAI tests in between 120% and
6300 ofpatients with benign breast disease
tested against breast-cancer antigens. The
test did appear to be tumour-type-
specific, in that false-positive results were
not obtained in patients with malignancies
other than HCC.
The absence of tube LAI reactivity in
the majority ofour patients with HCC may
reflect abrogation of specific tumnour im-
munity as a result of blocking of effector
cells by the systemic release of excess
soluble tumour antigen by a large tumour
mass. Certainly, tumour antigenic deter-
minants may absorb cytophilic anti-
tumour antibody (Thomson & Crosser,
1979). Leucocyte reactivity in experi-
mental animals with large tumour masses
has been shown to be diminished (Leveson
et al., 1977) and Grosser& Thomson (1975)
demonstrated a similar phenomenion in
patients with advanced breast cancer.
Recently, studies of LAI in pancreatic
(Tataryn et al., 1978), breast (Lopez et al.,
1977) and colorectal carcinomas (Shani
et al., 1978) differentiated patients with
localized disease from those with dissemin-
ated cancer. An excessive antigen load
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producing biockade ofmonocyte reactivity
may explain the reduction in specific
tumour immunity in our patients, all of
whom had large, rapidly growing tumouirs.
With the haemacytometer method,
LAI does not lessen withincreasing tumour
burden. Positive LAI tests have been
reported not only as an early manifesta-
tion of carcinoma (Halliday et al., 1974),
but also in disseminated malignancies. The
observation that LAIF production by sen-
sitized lymphocytes is detectable at all
stages of tumour growth and may increase
with advancing disease (Maluish, 1.979)
led us to evaluate patients with advanced
and in some instances pre-terminal HCC
with the haemacytometer method. The
results proved disappointing, however,
in that 47%0 ofpatients with histologically
proved HCC failed to give a positive
test with 2 different antigens. The
absence of LAI response in these pati-
ents cannot be satisfactorily explained.
Althoughi a-foetoprotein has been thought
to be immunosuppressive (Murgita &
Tomasi, 1 975) there was no statistically
significant difference in ca-foetoprotein
concentrations betweein the patients with
positive and negative LAI results. We
were also unable to distinguish, using a
variety of clinical and biochemical para-
meters, between those HCC patients with
positive LAI responses with either assay
and those with negative responses. That
not all antigens are reactive and induce
inhibition of leucocyte adherence is a
problem previously encountered in HoCC
(Halliday, W. J. personal commutnica-
tion) and antigenic heterogeneity may
explain negative results in several patients
tested against allogeneic extracts. Using a
pooled extract of 5 HCCs we obtainedl
positive responses in 3/5 patients. The
postulate that antigenlic differences exist
in HCC may be borne out by data of Lee
et al. (1977) utilizing another experimental
method. Assessing cell-medliated immune
reactions in -HCC, they found LAI in
520% of 25 patients witlh HCC wxhen tested
against 3 allogeneic KCl-extracted soluble
tumour antigens.
If antigenic differences are responsible
for limiting the diagnostic usefulness of
the LAI test, this might be overcome by
the use of a panel of antigens. Visual
counting, of cells is tedious and subjective
and automated techniques or image analy-
sis (Thomson et al., 1979) may obviatethese
shortcomings.
LAI assays may thus be potentially use-
ful research and diagnostic tools in the
investigation of tumour immunity, but
in this study, using crude membrane
extracts, they did not satisfy the need for
a rapid immunodiagnostic test in patients
with 11CC.
This work wN-as supported in part by a granit from
thle Nation-al Cancer Association of South Africa.
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